FMP
Oppenheimer Downgraded Spero Therapeutics to Perform From Outperform, Shares Down 4.67%.
Oct 01, 2021(Last modified: Dec 19, 2023)
Oppenheimer downgraded Spero Therapeutics, Inc. (NASDAQ:SPRO) to perform from outperform, providing the following key point for that decision:
(1) Stock trades near prior $20 price target
(2) unfavorable upside/downside from Revenue Interest Financing (RIF) into NDA review and commercial launch of Tebipenem,
(3) expectation for RIF financing covenants to complicate business development (relative to issuing equity or bank debt) including a potential sale of SPRO.
While the analysts acknowledge all companies should be managed for long-term value creation, with delay in SPR720 due to clinical hold and the prospect of 3–5 years of commercial organization only selling one product (Tebipenem), they view the company as likely to be either an acquirer of assets or seller of the company over the next 36 months.
Shares of Spero Therapeutics closed 4.67% lower on Friday.
WACC vs ROIC: Evaluating Capital Efficiency and Value Creation
Introduction In corporate finance, assessing how effectively a company utilizes its capital is crucial. Two key metri...
BofA Sees AI Capex Boom in 2025, Backs Nvidia and Broadcom
Bank of America analysts reiterated a bullish outlook on data center and artificial intelligence capital expenditures fo...
Pinduoduo Inc. (PDD) Q1 2025 Earnings Report Analysis
Pinduoduo Inc., listed on the NASDAQ as PDD, is a prominent e-commerce platform in China, also operating internationally...
